Biological markers of response for kidney cancer

To date, a reliable biomarker is yet to be discovered for the response of kidney cancer patients to treatment or for prognosis. In this review paper, Dr Robert Motzer and his research group from Memorial Sloan Kettering in the USA identified a set of 26 genes whose activity correlated with progression-free survival in the combination […]

read more

Pembrolizumab plus axitinib combination accepted by NHS Scotland for first-line treatment of advanced kidney cancer

The Sottish Medicine Consortium (SMC) have issued a final decision to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer. We are delighted that as from today, kidney cancer patients in Scotland can get NHS funding for pemrolizumab in combination with axitinib for untreated patients with advanced or metastatic renal cell […]

read more

Pembrolizumab plus axitinib combination declined for first-line treatment of advanced kidney cancer

The National Institute for Health and Care Excellence (NICE) have issued a final decision not to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer, despite it’s proven effectiveness at prolonging the life of kidney cancer patients. In their Final Appraisal Document (FAD) released today, NICE stated that there was uncertainty about the long-term benefits of the pembrolizumab plus axitinib […]

read more

Funding approved for avelumab in combination with axitinib for untreated advanced kidney cancer

KCSN are formal consultants to NICE and part of the process that appraises all new kidney cancer drugs. We are delighted to tell you that, as from today, kidney cancer patients can get NHS funding via the Cancer Drugs Fund for avelumab in combination with axitinib as a first-line treatment for patients with untreated advanced […]

read more

ASCO 2020: Pembrolizumab/axitinib combination for the treatment of advanced kidney cancer

Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC) were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program over the weekend. The combination of pembrolizumab with axitinib continues to show improved efficacy in the treatment of advanced RCC […]

read more

Axitinib effective as a third-line treatment for kidney cancer

A recent study published in the journal In Vivo assessed the therapeutic effect of axitinib as a third-line therapy following second-line nivolumab monotherapy in patients with metastatic renal cell carcinoma (RCC). Data from patients treated with axitinib as a third-line therapy after failure of first-line tyrosine kinase inhibitor (TKI) and second-line nivolumab monotherapy were reviewed. […]

read more

Promising efficacy and safety of seleno-L-methionine plus axitinib in advanced kidney cancer

Data from a recent phase I study of seleno-L-methionine in combination with axitinib (Inlyta) as treatment for patients with previously treated or relapsed clear cell renal cell carcinoma (ccRCC) were presented at the American Urological Association (AUA) Virtual Experience meeting over the weekend. There were 15 patients in the study with ccRCC whose disease had […]

read more

Axitinib first-line treatment of papillary renal cell carcinoma

The majority of renal cell carcinomas (RCCs) are a subtype called clear cell RCC. Most drugs have been developed to treat this subtype of RCC, leaving people with other metastatic RCC subtypes with an unmet need for an effective treatment in the first-line. Papillary RCC (pRCC) represents 10-15% of renal cell carcinomas, and is not an insignificant subtype. […]

read more

Individualised axitinib dosing for patients with metastatic kidney cancer

In the following video interview with Practice Update, Dr Nancy Davis from Vanderbilt University Medical Center in Nashville, Tennessee, USA talks about a study looking at individualised dosing of axitinib for patients with metastatic renal cell carcinoma (RCC) based on toxicity. This was a single-arm study in patients with metastatic predominately clear cell RCC who […]

read more

Evaluation of brain metastases in patients with kidney cancer treated with avelumab plus axitinib

In this video interview from Practice Update, Dr Eric Jonasch from MD Anderson Cancer Center in the USA talks about some interesting data on brain metastases in patients who have received a combination therapy. Renal cell carcinoma (RCC) patients will develop brain metastases in about 10% to 20% of the time, and the treatment for […]

read more
Showing 1 to 10 of 62 results
  TOP